British Journal of Pharmacology

British Journal of Pharmacology (2018) **175** 1785–1788 1785

Themed Section: Nicotinic Acetylcholine Receptors

EDITORIAL

Nicotinic acetylcholine receptors

Correspondence Professor Sue Wonnacott, Department of Biology & Biochemistry, University of Bath, Bath BA2 7HQ, UK.
E-mail: bsssw@bath.ac.uk

Sue Wonnacott[1], Isabel Bermudez[2], Neil S Millar[3] and Socrates J Tzartos[4]

[1]Department of Biology & Biochemistry, University of Bath, Bath, UK, [2]Department of Biological and Medical Sciences, Oxford Brookes University, Oxford, UK, [3]Department of Neuroscience, Physiology & Pharmacology, University College London, London, UK, and [4]Department of Neurobiology, Hellenic Pasteur Institute, Athens, Greece

This themed section of the *British Journal of Pharmacology* is the product of a conference that focussed on nicotinic ACh receptors (nAChRs) that was held on the Greek island of Crete from 7 to 11 May 2017. 'Nicotinic acetylcholine receptors 2017' was the fourth in a series of triennial international meetings that have provided a regular forum for scientists working on all aspects of nAChRs to meet and to discuss new developments. In addition to many of the regular participants, each meeting has also attracted a new group of scientists working in a fast-moving area of research. This themed section comprises both review articles and original research papers on nAChRs.

LINKED ARTICLES

This article is part of a themed section on Nicotinic Acetylcholine Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.11/issuetoc/

Abbreviations

LGIC, ligand-gated ion channel

Nicotinic acetylcholine receptors (nAChRs) have been major players in the history of pharmacology, from Langley's initial concept of a 'receptive substance' in 1905 (see Changeux, 2012) to Paton and Zaimis's (1949) pharmacological distinction of muscle and ganglionic nAChRs and Neher and Sakmann's functional analysis of nAChRs at the single-channel level (which was recognized with the 1991 Nobel Prize in Physiology & Medicine and is reviewed in this themed section by Bouzat and Sine, 2018). As the best characterized members of the family of ligand-gated ion channels (LGIC), nAChRs also became the protypical exemplar for the family of pentameric LGICs, including receptors for GABA (**$GABA_A$ receptors**), glycine **(Gly receptors**), 5-HT **(5-HT_3 receptors)** and glutamate (invertebrate GluCl receptors), as well as prokaryotic ancestors (Changeux, 2012).

The last 40 years or so have seen a shift of focus in nAChR research with the recognition that distinct 'neuronal nAChRs' occur in the CNS. The study of brain nAChRs was initially driven by the desire to understand **nicotine** dependence, responsible for tobacco smoking and its associated disease burden. Increasing awareness of the diversity of neuronal nAChRs, composed of subunits arising from a distinct family of genes from those expressed in skeletal muscle (Alexander *et al.*, 2017), has stimulated a broader interest in nAChRs, leading to drug discovery programmes for selective nicotinic therapeutic agents aimed at a wide range of neurological and mental health conditions. The subunit diversity and stoichiometry of nAChRs, and the associated pharmacology and clinical implications, are reviewed by Wang and Lindstrom (2018). Ten years ago, the burgeoning research into nAChRs inspired the first in a series of conferences, 'nAChRs 2008', hosted by the Wellcome Trust at Hinxton, Cambridge, UK. The success of this initial conference has been followed up every 3 years, with the latest conference, 'nAChRs 2017', being held in Crete in May 2017. The conference in Crete was a forum for presenting the latest developments in understanding the diversity, structure, function and clinical importance of nAChRs, with studies ranging from molecular to behavioural pharmacology.

© 2018 The British Pharmacological Society

DOI:10.1111/bph.14209

Structural and functional diversity of nAChRs

A consequence of subunit diversity for pentameric receptors is the generation of multiple heteromeric receptor subtypes, where differences in a single subunit can have profound or subtle influences on receptor pharmacology and channel function. Wang and Lindstrom (2018) provide an authoritative account of the complex pharmacology arising from distinct stoichiometries of neuronal nAChRs. They compare the contributions of 'orthodox' nAChR agonist-binding sites, at the interface between an α and β subunit, with 'unorthodox' sites that occur between two adjacent α subunits. The mechanistic influence of the fifth subunit, present between two orthodox agonist binding sites, is explored in the research paper by New *et al*. (2018).

In addition to the two classes of orthosteric site, nAChRs present numerous allosteric binding sites that allow either positive or negative modulation of agonist-evoked responses. Positive allosteric modulators have excited considerable interest as therapeutic candidates and the clinical implications of the considerable pharmacological heterogeneity of nAChRs are briefly reviewed (Wang and Lindstrom, 2018). Pharmacological complexity is further increased by considering the speed and duration of nAChR desensitization. Papke *et al*. (2018) compare a novel positive allosteric modulator and a 'silent desensitizer' (that converts the **α7 nAChR** into a desensitized state without detectable receptor activation). Both elicit long-lasting, but distinct, non-conducting conformations of the nAChR.

The **α3β2 and α3β4 nAChRs** are the predominant subtypes found in the peripheral nervous system and also occur in the brain and in non-neuronal cells. The exquisite pharmacological specificity of α-conotoxins, peptide toxins from marine cone snails, makes them attractive probes for discriminating nAChR subtypes, and α-conotoxins selectively targeting α3β4 nAChR subtypes are discussed by Cuny *et al*. (2018). Computer modelling and molecular dynamic simulations reveal the molecular basis for the ability of certain conopeptides to discriminate between α3-containing nAChR subtypes, which could form the basis for custom-designed selective ligands.

Important considerations in the generation of multiple nAChR subtypes are the factors that govern subunit assembly and trafficking of nAChRs. A timely review of this topic is provided by Gotti and colleagues (Crespi *et al*., 2018), covering endogenous protein chaperones, including RIC3, the Ly6 prototoxin family and the recently described NACHO, and exogenous pharmacological chaperones, notably nicotine.

Molecular structure and function

Drilling down to the intermolecular details of agonist recognition, the molecular architecture of orthosteric ligand binding sites derived from the recently elucidated first crystal structures of the neuronal nAChR is reviewed by Giastas *et al*. (2018). These authors consider the structural basis of pharmacological differences between nAChR subtypes, focussing on human nAChR isoforms and drawing comparisons with the wider family of pentameric LGICs. They also discuss functionally important interactions between structural elements of the neuronal nAChRs that seem to be conserved across the LGIC superfamily and are important for coupling agonist binding to channel opening. Functional measurements at the molecular level are provided by electrophysiological recordings of individual nAChRs. In an erudite review of this methodology, Bouzat and Sine (2018) also consider the effects of subunit stoichiometry and allosteric modulation. Another approach to modulating receptor activity is through photosensitive ligands that can act as optical switches; Bregestovski *et al*. (2018) review the history, applications and limitations of photo-switches in LGIC research.

Clinical implications

Because of the pervasive influence of the neurotransmitter **ACh** in central, peripheral and non-neuronal systems, it is not surprising that the cholinergic system is implicated in many disease states or their therapies. The generally modulatory nature of nAChRs residing outside the neuromuscular junction and autonomic synapses make them attractive therapeutic targets for enhancing or decreasing cholinergic transmission or tone. In the CNS, depression has been linked to increases in cholinergic activity, and the high prevalence of tobacco smoking among persons suffering from depression has led to the suggestion that depressed patients may try to use nicotine to dampen cholinergic signals, through nAChR desensitization. Consistent with this hypothesis, nAChR antagonists have some efficacy in animal models of depression. Picciotto and colleagues explored the role of α7 nAChRs in the hippocampus in anxiety-like and depression-like behaviours in mice (Mineur *et al*., 2018). Pharmacological antagonism or local knockdown of α7 nAChRs (using short hairpin RNAs) produced some significant amelioration in certain mouse models but, intriguingly, also revealed some striking gender differences.

Pain management is an area of great clinical need that has attracted much interest in the efficacy of nicotinic interventions. McIntosh and colleagues review the case for α9-containing nAChRs (**α9*nAChRs**) as therapeutic targets for treating neuropathic pain (Hone *et al*., 2018). The analgesic effects of certain α-conotoxins with high specificity for inhibiting α9*nAChRs, and the decreased pain sensitivity of α9 knockout mice, support a role for this nAChR subtype. However, the review is careful to point out inconsistencies in some research findings. The presence of α9*nAChRs in immune cells introduces immune cell-mediated inflammation as a potential mechanism to explain the efficacy of α9*nAChR blockade, and α9*nAChR-selective low MW antagonists are being characterized.

A change in hippocampal α7 nAChRs was observed in chronically nicotine-treated mice subjected to wheel running, described in a research paper from Bailey and colleagues (Keyworth *et al*., 2018). The purpose of this study was to evaluate the effect of exercise during chronic exposure to nicotine (*via* implanted minipump) on the severity of subsequent precipitated withdrawal. Wheel running reduced withdrawal symptoms and increased α7 nAChRs in nicotine-treated (but

not saline treated) mice, while **μ-opioid** and **dopamine D_2 receptors** were unaffected. These data implicate α7 nAChRs in the mechanism whereby exercise reduces subsequent nicotine withdrawal effects. It is interesting that exercise is also effective in countering depressive behaviours.

Another study into the effects of chronic nicotine on brain nAChRs, this time **α4β2 nAChRs**, was directed at determining the effect of gene dosage on consequent nAChR up-regulation (Moretti *et al.*, 2018). It is well established that chronic nicotine *in vivo* promotes the up-regulation of α4β2 nAChRs in rodent brain, mimicking changes observed in the *post-mortem* brain of tobacco smokers. Heterozygous mice lacking either one α4 allele or one β2 allele, or lacking one allele of each subunit, were compared with wild type mice for up-regulation of α4β2 nAChRs following chronic nicotine administration. α4 subunit heterozygotes produced a disproportionate degree of up-regulation compared with β2 heterozygotes and wild-type mice (Moretti *et al.*, 2018), suggesting that α4 polymorphisms that reduce α4 expression might produce enhanced responses to chronic nicotine, with implications for developing tobacco addiction.

Non-neuronal nAChRs

Nicotinic receptors are not limited to vertebrate nervous systems and the neuromuscular junction. 'Neuronal nAChRs' are also expressed by many non-neuronal cells including glia and immune cells, as already mentioned (Cuny *et al.*, 2018; Hone *et al.*, 2018). This non-neuronal locus challenges concepts of what ACh and nAChRs do, as well as warranting a more inclusive nomenclature! Two research papers in this themed section provide evidence that nAChRs expressed by cancer cells can drive proliferation. Mucchietto *et al.* (2018) report that nicotine (100 nM) promotes proliferation of lung adenocarcinoma cell lines *via* α7-containing and α9-containing nAChRs and suggest these nAChRs mediate pathophysiological effects of tobacco smoke in non-small-cell lung carcinoma. Consistent with this model, SLURP1 and SLURP2, endogenous peptide antagonists of α7 and non-α7 nAChRs, respectively, are reported to decrease the rate of cell proliferation in a variety of epithelial cancer cell lines, in the study of Lyukmanova *et al.* (2018).

Insect nAChRs

Nicotinic receptors also have important roles in invertebrates. They are the major vehicle for excitatory transmission in insect nervous systems, making them important targets for the agrochemical industry, particularly in areas of crop protection. This has led to the development of novel classes of insecticides such as the neonicotinoids (see Cartereau *et al.*, 2018). In this research paper, Steeve Thany and colleagues examine the effects of three neonicotinoids on mammalian α7 nAChRs. Their results show that these compounds are not potent agonists at rat α7 nAChRs, in contrast to their actions on nAChRs in insects (both pest and pollinating species), but novel modulatory actions were revealed. Molecular details of the interaction of neonicotinoids with *Drosophila* Dα1 subunit-containing nAChRs were examined by computer modelling, mutagenesis and oocyte electrophysiology, by Ihara *et al.* (2018).

Concluding remarks

This collection of reviews and research papers on nAChRs illustrates the breadth and calibre of current research into these receptors. The more we learn about their detailed molecular structures and mechanisms, and their physiological activities and contributions to disease models, so new questions and challenges are raised. The therapeutic potential of nAChRs remains to be fully exploited, but better understanding of the pharmacological manipulation of nAChRs will underpin the development of new nicotinic solutions for diverse clinical conditions. There is much to do, and we can anticipate further exciting developments for future nAChR conferences.

Acknowledgements

We thank all the authors who contributed to this themed section.

Conflict of interest

The authors of this editorial wish to acknowledge that they are co-authors of the articles by New *et al.* (I.B.) and Giastas *et al.* (S.T.) in this themed section.

References

Alexander SPH, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD *et al.* (2017). The Concise Guide to PHARMACOLOGY 2017/18: Ligand-gated ion channels. Br J Pharmacol 174: S130–S159.

Bouzat C, Sine SM (2018). Nicotinic acetylcholine receptors at the single-channel level. Br J Pharmacol 175: 1789–1804.

Bregestovski P, Maleeva G, Gorostiza P (2018). Light-induced regulation of ligand-gated channel activity. Br J Pharmacol 175: 1892–1902.

Cartereau A, Martin C, Thany SH (2018). Neonicotinoid insecticides differently modulate acetycholine-induced currents on mammalian α7 nicotinic acetylcholine receptors. Br J Pharmacol 175: 1987–1998.

Changeux JP (2012). The nicotinic acetylcholine receptor: the founding father of the pentameric ligand-gated ion channel superfamily. J Biol Chem 287: 40207–40215.

Crespi A, Colombo SF, Gotti C (2018). Proteins and chemical chaperones involved in neuronal nicotinic receptor expression and function: an update. Br J Pharmacol 175: 1869–1879.

Cuny H, Yu R, Tae H-S, Kompella SN, Adams DJ (2018). α-Conotoxins active at α3-containing nicotinic acetylcholine receptors and their molecular determinants for selective inhibition. Br J Pharmacol 175: 1855–1868.

Giastas P, Zouridakis M, Tzartos SJ (2018). Understanding structure–function relationships of the human neuronal

acetylcholine receptor: insights from the first crystal structures of neuronal subunits. Br J Pharmacol 175: 1880–1891.

Hone AJ, Servent D, McIntosh JM (2018). α9-containing nicotinic acetylcholine receptors and the modulation of pain. Br J Pharmacol 175: 1915–1927.

Ihara M, Hikida M, Matsushita H, Yamanaka K, Kishimoto Y, Kubo K *et al*. (2018). Loops D, E and G in the *Drosophila* Dα1 subunit contribute to high neonicotinoid sensitivity of Dα1-chicken β2 nicotinic acetylcholine receptor. Br J Pharmacol 175: 1999–2012.

Keyworth H, Georgiou P, Zanos P, Rueda AV, Chen Y, Kitchen I *et al*. (2018). Wheel running during chronic nicotine exposure is protective against mecamylamine-precipitated withdrawal and up-regulates hippocampal α7 nACh receptors in mice. Br J Pharmacol 175: 1928–1943.

Lyukmanova EN, Bychkov ML, Sharonov GV, Efremenko AV, Shulepko MA, Kulbatskii DS *et al*. (2018). Human secreted proteins SLURP-1 and SLURP-2 control the growth of epithelial cancer cells via interaction with nicotinic acetylcholine receptors. Br J Pharmacol 175: 1973–1986.

Mineur YS, Mose TN, Blakeman S, Picciotto MR (2018). Hippocampal α7 nicotinic ACh receptors contribute to modulation of depression-like behaviour in C57BL/6J mice. Br J Pharmacol 175: 1903–1914.

Moretti M, Fasoli F, Gotti C, Marks MJ (2018). Reduced α4 subunit expression in $\alpha4^{+-}$ and $\alpha4^{+-}/\beta2^{+-}$ nicotinic acetylcholine receptors alters α4β2 subtype up-regulation following chronic nicotine treatment. Br J Pharmacol 175: 1944–1956.

Mucchietto V, Fasoli F, Pucci S, Moretti M, Benfante R, Maroli A *et al*. (2018). α9- and α7-containing receptors mediate the pro-proliferative effects of nicotine in the A549 adenocarcinoma cell line. Br J Pharmacol 175: 1957–1972.

New K, Garcia Del Villar S, Mazzaferro S, Alcaino C, Bermudez I (2018). The fifth subunit of the $(\alpha4\beta2)_2\beta2$ nicotinic ACh receptor modulates maximal ACh responses. Br J Pharmacol 175: 1822–1837.

Papke RL, Stokes C, Damaj MI, Thakur GA, Manther K, Treinin M *et al*. (2018). Persistent activation of α7 nicotinic ACh receptors associated with stable induction of different desensitized states. Br J Pharmacol 175: 1838–1854.

Paton WDM, Zaimis EJ (1949). The pharmacological actions of polymethylene bistrimethylammonium salts. Br J Pharmacol 4: 381–397.

Wang J, Lindstrom J (2018). Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors. Br J Pharmacol 175: 1805–1821.